CD34+ cell dose predicts costs after autologous peripheral blood stem cell transplantation for breast cancer.

We assessed the effect of CD34+ cell dose on costs in breast cancer patients undergoing autologous peripheral blood stem cell (PBSC) transplantation. Mean hospitalization costs were 26,992.9+/-9582.